Researchers have conducted a gold‑standard systematic review of existing literature to evaluate the safety of paracetamol use throughout pregnancy, aiming to resolve ongoing debate. The study aggregated data from multiple observational studies and randomized trials, providing a quantitative assessment of neonatal and maternal outcomes associated with paracetamol exposure. bA comprehensive meta‑analysis was performed/b to determine relative risk values for adverse events, incorporating standardized methodological criteria to ensure robustness. bThe findings consistently show no significant increase in fetal complications or developmental disorders when paracetamol is used within recommended dosing limits during gestation./b bThus, the evidence supports continued use of paracetamol for pain and fever management in pregnant individuals, invalidating prior claims linking the medication to autism./b _2_ The review methodology followed PRISMA guidelines, and the inclusion criteria encompassed studies published over the past two decades across diverse geographic regions and populations. Statistical analyses yielded a pooled risk ratio close to unity, indicating neutrality between exposed and non‑exposed cohorts. Subgroup analyses for trimester‑specific exposure revealed no dose‑dependent risks, reinforcing the consistency of safety signals. _3_ The implications of these findings extend to clinical practice, caregiving guidelines, and public health communication. By providing high‑confidence evidence, the study offers a resource for obstetricians to counsel expectant patients accurately, discouraging unwarranted discontinuation of paracetamol and mitigating medication‑avoidance behaviors that may result in alternative, less effective pain control strategies. This contributes to more informed healthcare decisions and supports continued research into comparative analgesic safety profiles during pregnancy.